

AUG 15 2007

Application No.: 09/851,614

Docket No.: CDJ-166RCE

REMARKS

Claims 94 and 99-107 were pending in the application. Claims 94-98 have been canceled without prejudice. Claims 100-107 have been amended.

Claims 100-107 have been amended to provide appropriate claim dependency.

The foregoing claim amendments should in no way be construed as acquiescence to any of the Examiner's rejections and were made solely to expedite prosecution of the application. Applicants reserve the right to pursue claims to the canceled subject matter, or any subject matter which they are entitled to claim, in this or a separate application. No new matter has been added.

Rejection of Claims 94 and 99-107 Under 35 U.S.C. §112, First Paragraph

Claims 94 and 99-107 are rejected as containing new matter. Specifically, the Examiner alleges that "the specification and the claims as originally filed do not provide support for the invention as now claimed." Applicants address each of the individual issues raised by the Examiner below.

A) With respect to claim 94, the Examiner asserts that "... the specification does not adequately describe antibodies comprising the claimed CDRs."

First, Applicants note that the Examiner's current characterization of the subject matter of claim 94 (as defining only the CDR3 heavy and light chain variable region CDRs) is incorrect. Claim 94 comprises all six specific heavy and light chain CDR1, CDR2 and CDR3 sequences.

Applicants respectfully traverse this rejection at least for the reasons set forth in their previous responses. However, to expedite prosecution, claim 94 has been canceled without prejudice.

B) With respect to the Examiner's rejection of claims 95-98, this rejection is moot since claims 95-98 are no longer pending in the current application.

C) With respect to claim 99, Applicants respectfully note that this claim no longer refers to "conservative sequence modifications." Moreover, support for amended claim 99, which is drawn to an isolated human monoclonal antibody (or antigen binding portion thereof) that binds to human dendritic cells and has particular human heavy and light chain variable

Application No.: 09/851,614

Docket No.: CDJ-166RCE

region amino acid sequences (*i.e.*, SEQ ID NOS: 4 and 2, respectively), can be found throughout the specification as originally filed, *e.g.*, Figure 13 and original claim 51.

D) With respect to claims 100-107, as they depend from claim 99, Applicants respectfully traverse for the reasons set forth above.

Rejection of Claims 94 and 99-107 Under 35 U.S.C. §112, First Paragraph

Claims 94 and 99-107 are rejected as not meeting the written description requirement with regard to "conservative sequence modifications."

Applicants respectfully traverse this rejection. However, to expedite prosecution, claim 94 has been canceled without prejudice. Further, claim 99 has been amended (in Applicants' response dated March 28, 2007) so that this claim (and dependent claims 100-107) no longer refer to "conservative sequence modifications." Accordingly, this rejection is moot.

Rejection of Claims 94 and 99-107 Under 35 U.S.C. §112, First Paragraph

Claims 94 and 99-107 are rejected as not being enabled because, according to the Examiner, "the claims recite no limitations on the number of amino acids that can be 'modified' and 'no examples of modified antibodies...are disclosed.'"

Applicants respectfully traverse this rejection. However, as indicated above, to expedite prosecution, Applicants have canceled claim 94 and have amended claim 99 so as to no longer refer to "conservative sequence modifications." Therefore, this rejection is now moot.

AUG 15 2007

Application No.: 09/851,614

Docket No.: CDJ-166RCE


CONCLUSION

Based on the foregoing amendments and arguments, reconsideration and withdrawal of all the rejections, and allowance of this application with all pending claims are respectfully requested. If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 227-7400.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CDJ-166RCE.

Dated: August 15, 2007

Respectfully submitted,

By 
Jill Gorny Sloper, Esq.
Registration No.: 60,760
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant